Amgen Inc. (AMGN), one of the world's largest biotechnology companies, has delivered a standout 2026 — rallying roughly 37% year to date to around $439. The question for investors is whether that momentum can carry the shares to $500, a level that sits above every prior closing high and above the broad analyst consensus. Here is a balanced look at what that target represents, what could support it, and what could stand in the way.
Because Amgen has rallied so quickly, this figure is drawn from public discussion and the most bullish published targets rather than a headline consensus. The average analyst price target currently sits below the stock: MarketBeat's aggregation of 30 analysts points to roughly $386, while S&P Global's polling of 34 analysts shows about $395 — both beneath the $438.94 close. The full range is unusually wide, from a cautious $185 initiation at Barclays to $500 at the high end, after Scotiabank lifted its target to $500 from $450 in early October. Other recent moves illustrate the split: UBS raised its target to $470 with a Buy rating, Piper Sandler reaffirmed a Buy at $457, while Morgan Stanley stood at $359 with a Hold.
Because the broad consensus is below the market price, the $500 figure is best understood as a Street-high, psychological target — the level at which the most optimistic analysts and momentum-oriented investors see the next leg higher. It should not be read as an official consensus.
At $438.94, reaching $500 implies roughly 14% upside — a substantial move for a large-cap healthcare name, though not an extreme one after a 49% one-year gain. The shares sit just below their 52-week and all-time high of $447.03, meaning the path to $500 first requires clearing that record and then extending into uncharted territory.
The fundamental picture supports the rally: second-quarter revenue topped $10 billion (up about 10% year over year), adjusted EPS (earnings per share) of $6.29 beat expectations, and management raised full-year guidance to roughly $38.2–$39.4 billion in revenue with adjusted EPS of $22.30–$23.50. Amgen now has 17 products generating more than $1 billion in annual sales, and its six core growth products grew about 26% year over year. At about 18 times forward earnings, the stock trades at a discount to its large-cap biotech peers, which some analysts cite as room for further re-rating.
The shares are consolidating just under their record high of $447.03, a clear resistance level that must be broken before $500 becomes reachable. Recent pullbacks found support in the $410–$415 zone, with a broader support area around $385–$400 aligning with the consensus price targets. $500 itself is a psychological round number with no prior trading history above $447, so any approach would rely on sustained momentum rather than established technical structure.
Analyst price targets typically reflect a roughly 12-month horizon, though the unusually wide $185-to-$500 spread shows how differently firms weigh the same pipeline. The next earnings report is scheduled for early November, a key checkpoint for guidance and MariTide commentary. Beyond that, investors should watch Phase III obesity and cardiovascular readouts, analyst target revisions, biosimilar competition for legacy products, and any resolution of the IRS dispute.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a fast-moving name like Amgen — trading near record highs with a wide analyst spread — such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review. Consider exploring the AI Daily Buy/Sell Signals to complement your own research.
The $500 question for Amgen is fundamentally a bet on momentum and the obesity pipeline rather than a reflection of the average analyst view, which still sits below the current price. A roughly 14% move to $500 would require clearing the $447 record and delivering on MariTide — the catalyst the bulls are most counting on — while navigating biosimilar erosion, tax uncertainty, and a valuation that has already re-rated sharply. The unusually wide analyst range, from $185 to $500, underscores genuine disagreement about how much further the story can run. The outcome will likely hinge on the upcoming earnings report and subsequent pipeline data rather than on any single valuation metric.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -1.79% | ||
| PFE - AMGN | 51% Loosely correlated | -1.28% | ||
| GILD - AMGN | 48% Loosely correlated | -0.73% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.16% | ||
| BIIB - AMGN | 47% Loosely correlated | -1.24% | ||
| MRK - AMGN | 47% Loosely correlated | -1.34% | ||
More | ||||